68Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis

Area of Science:

• Nuclear medicine
• Cardiology
• Oncology

Background:

• Cardiac sarcoidosis (CS) presents a poor prognosis due to arrhythmias and heart failure.
• Current treatments involve anti-inflammatory drugs and cardiac device implantation.
• Cardiac devices and myocardial glucose uptake limit the diagnostic accuracy of cardiac MRI and F-FDG PET/CT.

Purpose of the Study:

• To evaluate the diagnostic utility of somatostatin-based PET/CT, specifically Ga-DOTATOC PET/CT, for active cardiac sarcoidosis.
• To address the limitations of F-FDG PET/CT in diagnosing CS, particularly in patients with cardiac devices.

Main Methods:

• Utilized Ga-DOTATOC PET/CT imaging in patients with suspected or confirmed cardiac sarcoidosis.
• Compared Ga-DOTATOC PET/CT findings with F-FDG PET/CT and clinical data.
• Focused on challenging clinical scenarios, including refractory CS and patients with implanted cardiac devices.

Main Results:

• Ga-DOTATOC PET/CT demonstrates high specificity in identifying active granulomatosis in CS.
• This method is effective in challenging cases, such as refractory CS.
• Ga-DOTATOC PET/CT provides valuable diagnostic information in patients with cardiac devices, overcoming F-FDG PET/CT limitations.
• It helps differentiate true CS activity from non-specific inflammation or false-positive F-FDG PET/CT results.

Conclusions:

• Ga-DOTATOC PET/CT is a specific imaging modality for active cardiac sarcoidosis.
• It offers a valuable alternative to F-FDG PET/CT in patients with cardiac devices or refractory disease.
• This technique enhances diagnostic accuracy in complex CS cases.